Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z. Usmani, Amrita Krishnan, Hareth Nahi et al.|The Lancet|2021Cited by 321
Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) <b>×</b> CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).Amrita Krishnan, Alfred L. Garfall, María‐Victoria Mateos et al.|Journal of Clinical Oncology|2021Cited by 15